Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Active not recruiting 3

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Gastrointestinal 1CNS 1

Conditions

Small Cell Lung Carcinoma 4Lung Neoplasms 3Ovarian Neoplasms 2Fallopian Tube Neoplasms 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1HRD Cancer 1Colorectal Neoplasms 1Clinical Stage III Gastric Cancer AJCC v8 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Specimen Handling 53pembrolizumab 51Carboplatin 51Magnetic Resonance Spectroscopy 46Pemetrexed 41Cisplatin 36Paclitaxel 25durvalumab 24osimertinib 22Nivolumab 22Gemcitabine 20Radiosurgery 18Radiotherapy 17Docetaxel 17atezolizumab 15Immunoglobulin G 15Biopsy 15Disulfides 14130-nm albumin-bound paclitaxel 13Taxes 12Radiation 12Educational Status 12Etoposide 11Blood Specimen Collection 11Early Intervention, Educational 10Drug Therapy 10Practice Guidelines as Topic 9Platinum 9Methods 9Cetuximab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Lung Neoplasms × berzosertib × 90 days × Clear all
NCT04216316 2026-05-28

Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
12 enrolled 25 charts
Thoracic

Lung Neoplasms

NCT02595931 2026-05-13

M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1 Active not recruiting
66 enrolled
GastrointestinalThoracic

Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

NCT02589522 2026-04-29

Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
15 enrolled 10 charts
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡